Loading…
Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia
Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the eff...
Saved in:
| Published in: | BMC veterinary research 2019-10, Vol.15 (1), p.371-371, Article 371 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c565t-7425220dda890419292f977bbafbb881293691631600cfeb255f3d304155e19f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c565t-7425220dda890419292f977bbafbb881293691631600cfeb255f3d304155e19f3 |
| container_end_page | 371 |
| container_issue | 1 |
| container_start_page | 371 |
| container_title | BMC veterinary research |
| container_volume | 15 |
| creator | Dudek, Katarzyna Bednarek, Dariusz Ayling, Roger D Kycko, Anna Reichert, Michał |
| description | Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the effectiveness of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; and a group with an additional treatment of pegbovigrastim, an immunostimulator, was evaluated.
Enrofloxacin given alone stimulated a strong immune response, reduced the clinical manifestation and lung lessions of the M. bovis infection. In contrast the combination therapy appeared ineffective.
In this experiment enrofloxacin given alone appeared to be the most effective treatment of the M. bovis affected calves, whereas co-administration with flunixin meglumine, and pegbovigrastim was not beneficial in this trial. |
| doi_str_mv | 10.1186/s12917-019-2122-3 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_49ecae18b1db4e96b6ccc1e0c6425f54</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A604549489</galeid><doaj_id>oai_doaj_org_article_49ecae18b1db4e96b6ccc1e0c6425f54</doaj_id><sourcerecordid>A604549489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c565t-7425220dda890419292f977bbafbb881293691631600cfeb255f3d304155e19f3</originalsourceid><addsrcrecordid>eNqNUlFv1iAUbYzGzU9_gC-GxJc92AkUaHkxWRZ1S2b0QZ8JpZeOpYUK7bLv30vttuxLfDCEQC7nnHsPOUXxluBTQhrxMREqSV1iIktKKC2rZ8UxqZkoBWHN8yf3o-JVSjcYMyZr8bI4qojgnEt-XCw_IgxudF7HPUrz0u1R8Gi-BgTWgpkTChaBj8EO4U4b5z8gOyze3TmPRuiHJVMBad-hCfo23Lo-6jS7cVX5tjdhGnQaNVpfEpo8LGPwTr8uXlg9JHhzf-6KX18-_zy_KK--f708P7sqDRd8LmtGOaW463QjMSOSSmplXbettm3bNNl9JSQR2Q3GxkJLObdVV2Uo50CkrXbF5abbBX2jpujGbFMF7dTfQoi90nF2ZgDFJBgNpGlJ1zKQohXGGALYiDyE5Sxrfdq0pqUdoTPg56iHA9HDF--uVR9ulWgIZ3nUXXFyLxDD7wXSrEaXDAyD9hCWpGhVcVKJvP8DimWDmxqv0PcbtNfZhfM25OZmhaszgRlnkjVr79N_oPLqYHQmeLAu1w8IZCOYGFKKYB-NEqzW8KktfCqHT63hU-so757-0CPjIW3VH2Wt1bw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2309808703</pqid></control><display><type>article</type><title>Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Dudek, Katarzyna ; Bednarek, Dariusz ; Ayling, Roger D ; Kycko, Anna ; Reichert, Michał</creator><creatorcontrib>Dudek, Katarzyna ; Bednarek, Dariusz ; Ayling, Roger D ; Kycko, Anna ; Reichert, Michał</creatorcontrib><description>Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the effectiveness of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; and a group with an additional treatment of pegbovigrastim, an immunostimulator, was evaluated.
Enrofloxacin given alone stimulated a strong immune response, reduced the clinical manifestation and lung lessions of the M. bovis infection. In contrast the combination therapy appeared ineffective.
In this experiment enrofloxacin given alone appeared to be the most effective treatment of the M. bovis affected calves, whereas co-administration with flunixin meglumine, and pegbovigrastim was not beneficial in this trial.</description><identifier>ISSN: 1746-6148</identifier><identifier>EISSN: 1746-6148</identifier><identifier>DOI: 10.1186/s12917-019-2122-3</identifier><identifier>PMID: 31655595</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Animals ; Anti-Bacterial Agents - therapeutic use ; Anti-inflammatory agents ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; antibiotic resistance ; calves ; Carprofen ; Cattle ; cattle diseases ; Cattle Diseases - drug therapy ; Cattle Diseases - microbiology ; Clonixin - analogs & derivatives ; Clonixin - therapeutic use ; Diagnosis ; Drug Therapy, Combination - veterinary ; enrofloxacin ; Enrofloxacin - therapeutic use ; etiological agents ; Europe ; Female ; Flunixin ; Fluoroquinolones ; Granulocyte Colony-Stimulating Factor - therapeutic use ; Health aspects ; Immune response ; Immunotherapy ; Infection ; lungs ; Mycoplasma bovis ; Mycoplasma bovis - drug effects ; Mycoplasma Infections - drug therapy ; Mycoplasma Infections - veterinary ; nonsteroidal anti-inflammatory agents ; Pegbovigrastim ; Pneumonia ; Pneumonia - drug therapy ; Pneumonia - veterinary ; Recombinant Proteins - therapeutic use ; Risk factors ; therapeutics ; Vaccines</subject><ispartof>BMC veterinary research, 2019-10, Vol.15 (1), p.371-371, Article 371</ispartof><rights>COPYRIGHT 2019 BioMed Central Ltd.</rights><rights>The Author(s). 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c565t-7425220dda890419292f977bbafbb881293691631600cfeb255f3d304155e19f3</citedby><cites>FETCH-LOGICAL-c565t-7425220dda890419292f977bbafbb881293691631600cfeb255f3d304155e19f3</cites><orcidid>0000-0002-3271-3748</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815429/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815429/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,36990,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31655595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dudek, Katarzyna</creatorcontrib><creatorcontrib>Bednarek, Dariusz</creatorcontrib><creatorcontrib>Ayling, Roger D</creatorcontrib><creatorcontrib>Kycko, Anna</creatorcontrib><creatorcontrib>Reichert, Michał</creatorcontrib><title>Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia</title><title>BMC veterinary research</title><addtitle>BMC Vet Res</addtitle><description>Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the effectiveness of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; and a group with an additional treatment of pegbovigrastim, an immunostimulator, was evaluated.
Enrofloxacin given alone stimulated a strong immune response, reduced the clinical manifestation and lung lessions of the M. bovis infection. In contrast the combination therapy appeared ineffective.
In this experiment enrofloxacin given alone appeared to be the most effective treatment of the M. bovis affected calves, whereas co-administration with flunixin meglumine, and pegbovigrastim was not beneficial in this trial.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-inflammatory agents</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>antibiotic resistance</subject><subject>calves</subject><subject>Carprofen</subject><subject>Cattle</subject><subject>cattle diseases</subject><subject>Cattle Diseases - drug therapy</subject><subject>Cattle Diseases - microbiology</subject><subject>Clonixin - analogs & derivatives</subject><subject>Clonixin - therapeutic use</subject><subject>Diagnosis</subject><subject>Drug Therapy, Combination - veterinary</subject><subject>enrofloxacin</subject><subject>Enrofloxacin - therapeutic use</subject><subject>etiological agents</subject><subject>Europe</subject><subject>Female</subject><subject>Flunixin</subject><subject>Fluoroquinolones</subject><subject>Granulocyte Colony-Stimulating Factor - therapeutic use</subject><subject>Health aspects</subject><subject>Immune response</subject><subject>Immunotherapy</subject><subject>Infection</subject><subject>lungs</subject><subject>Mycoplasma bovis</subject><subject>Mycoplasma bovis - drug effects</subject><subject>Mycoplasma Infections - drug therapy</subject><subject>Mycoplasma Infections - veterinary</subject><subject>nonsteroidal anti-inflammatory agents</subject><subject>Pegbovigrastim</subject><subject>Pneumonia</subject><subject>Pneumonia - drug therapy</subject><subject>Pneumonia - veterinary</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Risk factors</subject><subject>therapeutics</subject><subject>Vaccines</subject><issn>1746-6148</issn><issn>1746-6148</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqNUlFv1iAUbYzGzU9_gC-GxJc92AkUaHkxWRZ1S2b0QZ8JpZeOpYUK7bLv30vttuxLfDCEQC7nnHsPOUXxluBTQhrxMREqSV1iIktKKC2rZ8UxqZkoBWHN8yf3o-JVSjcYMyZr8bI4qojgnEt-XCw_IgxudF7HPUrz0u1R8Gi-BgTWgpkTChaBj8EO4U4b5z8gOyze3TmPRuiHJVMBad-hCfo23Lo-6jS7cVX5tjdhGnQaNVpfEpo8LGPwTr8uXlg9JHhzf-6KX18-_zy_KK--f708P7sqDRd8LmtGOaW463QjMSOSSmplXbettm3bNNl9JSQR2Q3GxkJLObdVV2Uo50CkrXbF5abbBX2jpujGbFMF7dTfQoi90nF2ZgDFJBgNpGlJ1zKQohXGGALYiDyE5Sxrfdq0pqUdoTPg56iHA9HDF--uVR9ulWgIZ3nUXXFyLxDD7wXSrEaXDAyD9hCWpGhVcVKJvP8DimWDmxqv0PcbtNfZhfM25OZmhaszgRlnkjVr79N_oPLqYHQmeLAu1w8IZCOYGFKKYB-NEqzW8KktfCqHT63hU-so757-0CPjIW3VH2Wt1bw</recordid><startdate>20191026</startdate><enddate>20191026</enddate><creator>Dudek, Katarzyna</creator><creator>Bednarek, Dariusz</creator><creator>Ayling, Roger D</creator><creator>Kycko, Anna</creator><creator>Reichert, Michał</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3271-3748</orcidid></search><sort><creationdate>20191026</creationdate><title>Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia</title><author>Dudek, Katarzyna ; Bednarek, Dariusz ; Ayling, Roger D ; Kycko, Anna ; Reichert, Michał</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c565t-7425220dda890419292f977bbafbb881293691631600cfeb255f3d304155e19f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-inflammatory agents</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>antibiotic resistance</topic><topic>calves</topic><topic>Carprofen</topic><topic>Cattle</topic><topic>cattle diseases</topic><topic>Cattle Diseases - drug therapy</topic><topic>Cattle Diseases - microbiology</topic><topic>Clonixin - analogs & derivatives</topic><topic>Clonixin - therapeutic use</topic><topic>Diagnosis</topic><topic>Drug Therapy, Combination - veterinary</topic><topic>enrofloxacin</topic><topic>Enrofloxacin - therapeutic use</topic><topic>etiological agents</topic><topic>Europe</topic><topic>Female</topic><topic>Flunixin</topic><topic>Fluoroquinolones</topic><topic>Granulocyte Colony-Stimulating Factor - therapeutic use</topic><topic>Health aspects</topic><topic>Immune response</topic><topic>Immunotherapy</topic><topic>Infection</topic><topic>lungs</topic><topic>Mycoplasma bovis</topic><topic>Mycoplasma bovis - drug effects</topic><topic>Mycoplasma Infections - drug therapy</topic><topic>Mycoplasma Infections - veterinary</topic><topic>nonsteroidal anti-inflammatory agents</topic><topic>Pegbovigrastim</topic><topic>Pneumonia</topic><topic>Pneumonia - drug therapy</topic><topic>Pneumonia - veterinary</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Risk factors</topic><topic>therapeutics</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dudek, Katarzyna</creatorcontrib><creatorcontrib>Bednarek, Dariusz</creatorcontrib><creatorcontrib>Ayling, Roger D</creatorcontrib><creatorcontrib>Kycko, Anna</creatorcontrib><creatorcontrib>Reichert, Michał</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>BMC veterinary research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dudek, Katarzyna</au><au>Bednarek, Dariusz</au><au>Ayling, Roger D</au><au>Kycko, Anna</au><au>Reichert, Michał</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia</atitle><jtitle>BMC veterinary research</jtitle><addtitle>BMC Vet Res</addtitle><date>2019-10-26</date><risdate>2019</risdate><volume>15</volume><issue>1</issue><spage>371</spage><epage>371</epage><pages>371-371</pages><artnum>371</artnum><issn>1746-6148</issn><eissn>1746-6148</eissn><abstract>Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the effectiveness of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; and a group with an additional treatment of pegbovigrastim, an immunostimulator, was evaluated.
Enrofloxacin given alone stimulated a strong immune response, reduced the clinical manifestation and lung lessions of the M. bovis infection. In contrast the combination therapy appeared ineffective.
In this experiment enrofloxacin given alone appeared to be the most effective treatment of the M. bovis affected calves, whereas co-administration with flunixin meglumine, and pegbovigrastim was not beneficial in this trial.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>31655595</pmid><doi>10.1186/s12917-019-2122-3</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3271-3748</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-6148 |
| ispartof | BMC veterinary research, 2019-10, Vol.15 (1), p.371-371, Article 371 |
| issn | 1746-6148 1746-6148 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_49ecae18b1db4e96b6ccc1e0c6425f54 |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Adjuvants, Immunologic - therapeutic use Animals Anti-Bacterial Agents - therapeutic use Anti-inflammatory agents Anti-Inflammatory Agents, Non-Steroidal - therapeutic use antibiotic resistance calves Carprofen Cattle cattle diseases Cattle Diseases - drug therapy Cattle Diseases - microbiology Clonixin - analogs & derivatives Clonixin - therapeutic use Diagnosis Drug Therapy, Combination - veterinary enrofloxacin Enrofloxacin - therapeutic use etiological agents Europe Female Flunixin Fluoroquinolones Granulocyte Colony-Stimulating Factor - therapeutic use Health aspects Immune response Immunotherapy Infection lungs Mycoplasma bovis Mycoplasma bovis - drug effects Mycoplasma Infections - drug therapy Mycoplasma Infections - veterinary nonsteroidal anti-inflammatory agents Pegbovigrastim Pneumonia Pneumonia - drug therapy Pneumonia - veterinary Recombinant Proteins - therapeutic use Risk factors therapeutics Vaccines |
| title | Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T13%3A03%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20study%20on%20the%20effects%20of%20enrofloxacin,%20flunixin%20meglumine%20and%20pegbovigrastim%20on%20Mycoplasma%20bovis%20pneumonia&rft.jtitle=BMC%20veterinary%20research&rft.au=Dudek,%20Katarzyna&rft.date=2019-10-26&rft.volume=15&rft.issue=1&rft.spage=371&rft.epage=371&rft.pages=371-371&rft.artnum=371&rft.issn=1746-6148&rft.eissn=1746-6148&rft_id=info:doi/10.1186/s12917-019-2122-3&rft_dat=%3Cgale_doaj_%3EA604549489%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c565t-7425220dda890419292f977bbafbb881293691631600cfeb255f3d304155e19f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2309808703&rft_id=info:pmid/31655595&rft_galeid=A604549489&rfr_iscdi=true |